Dr. Dai Horiuchi

Assistant Professor of Pharmacology

Northwestern University Feinberg School of Medicine

Dr. Dai Horiuchi’s ongoing breast cancer research is geared toward identifying new therapeutic strategies for triple-negative breast cancer (TNBC). Triple-negative tumors are the breast cancer subtype with the poorest clinical outcome, presenting serious challenges for patients and researchers. Dr. Horiuchi investigates tumor generation and progression, as well as validating novel and safer therapies.

As a Lynn Sage Scholar, Dr. Horiuchi is studying a family of proteins as an immuno-oncology target for TNBC tumors. His laboratory utilizes bioinformatics, sophisticated screening strategies, and collaborations with clinicians and pharmaceutical partners. He is dedicated to bringing his laboratory findings to clinical testing in order to significantly reduce TNBC-related mortality.

Dr. Horiuchi arrived at Northwestern University Feinberg School of Medicine in 2015, and is a member of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center. He received his doctorate from Indiana University in cell and molecular biology. Dr. Horiuchi conducted his postdoctoral fellowship at University of California, San Francisco, where he was a member of the Breast Cancer Oncology Program within UCSF Helen Diller Family Comprehensive Cancer Center.